2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - New Orleans Theatre A
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, CHIP, Genomics, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, T Cell Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

791 Romidepsin primes cutaneous T-cell lymphoma cells for brentuximab vedotin by attenuating interferon programs and inducing an apoptosis-susceptible state: A phase 1 clinical trial

Luca Paruzzo, MD, Tatyana Feldman, MD2, Jennifer A. DeSimone3, Joseph Fraietta, PhD4, Ellen Kim5, Bernhard Dumoulin6, Pooja Devi, MD7, Patrizia Porazzi, PhD8, Antonio Imparato, MD9, Jina Chung10, Karthik Devajaran11, Katalin Susztak12, Yibin Yang, PhD13, Henry C.H. Fung14, Tafseer Mahvish15, Nadia Khan, MD16, Shazia Nakhoda, MD17, Marco Ruella, MD18, Stefan K Barta, MD19
1 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Hackensack University Medical Center, Hackensack, New Jersey, United States
3 Melanoma and Skin Oncology Center, INOVA, Fairfax, Virginia, United States
4 Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 Department of Dermatology, University of Pennsylvania, Philadelphia, United States
6 Renal, Electrolyte, and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 Division of pathology and laboratory medicine, Hospital of the University of Pennsylvania, Philadelphia, United States
8 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 Department of Dermatology, University of Pennsylvania, Philadelphia, United States
11 The Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, philadelphia, United States
12 Renal, Electrolyte, and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
13 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
14 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
15 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
16 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States, Swedish Cancer Institute, Seattle, United States
17 Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, United States
18 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
19 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Background:

Patients (pts) with relapsed/refractory cutaneous T-cell lymphoma (CTCL) have limited treatment options, in part because of a protumorigenic tumor microenvironment (TME).Brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate (ADC), is effective in ≈50% of the patients, but responses are not durable. Romidepsin (Ro), a histone deacetylase inhibitor (HDACi), has both a potent single-agent activity and a profound immunomodulatory effect on the TME. We hypothesized that Ro would alter the CTCL transcriptional profile, enhancing susceptibility to ADC-mediated cytotoxicity. Thus, we evaluated the safety, clinical activity, and biological effects of Ro plus BV (Ro-BV) in pts with advanced CTCL irrespective of baseline CD30 expression.

Methods:
In this investigator-initiated phase 1 study (NCT02616965), pts with mycosis fungoides (MF) or Sézary syndrome (SS) received romidepsin alone on day -14, followed by Ro-BV. A 3+3 dose-escalation design included four dose levels beginning at DL0 (DL -2, -1, 0, & 1). Clinical responses were evaluated globally and within skin, blood, and nodal/visceral compartments. Paired tumor biopsies collected before and after a single Ro dose were evaluated for CD30 expression (n=11). Four paired biopsies (n=8 total samples) were analyzed using spatial transcriptomic profiling (CosMx Human 6K Discovery Panel). Differential gene expression (DEG) analysis was performed at the CTCL-cell level using a false discovery rate of 0.05.

Results:
Fifteen pts received treatment (13 MF and 2 SS). Median age was 65 years, 83% were male, and 87% had stage IIB–IV disease. Pts received a median of 2 prior systemic therapies. No dose-limiting toxicities (DLTs) occurred at DL0 (n=3). At DL1, 1/12 pts experienced a DLT (grade 3 fatigue); DL1 was therefore established as the MTD and RP2D.  Most treatment-related adverse events were grade 1–2 (mostly gastrointestinal); grade 3–4 events occurred in 3 pts (fatigue, fever, transaminitis). One pt discontinued treatment for toxicity (fatigue).

Among 13 efficacy-evaluable pts, the global overall response rate was 77% (Skin: 77%, Blood:100%, Lymph node/viscera: 71%). At a median follow-up of 22.4 months, median PFS was 339 days, median DOR was 231 days, and median OS was not reached. We observed a significant improvement in skin-related quality of life: median 31-point reduction in the overall Skindex-16 score (P<0.05).

Given the observed clinical responses, we investigated romidepsin-mediated synergy and immunomodulatory effect. We first tested whether Ro increases CD30 expression in cancer cells. The median pretreatment H-score was 10 (range, 0–120), whereas the median post-treatment H-score was 0 (range, 0–240). No increase in CD30 expression was observed among pts with absent or low baseline expression (H-score 0–20; n=7). However, among pts with higher baseline CD30 expression (H-score >50, n=4), a numerical increase in CD30 H-score was observed (median pre: 90 vs post: 150, p=0.12).

We next characterized tumor-cell transcriptional changes after romidepsin priming. We profiled 241,657 spatially resolved cells (67,753 pre-Ro and 173,904 post-Ro), including 37,946 CTCL cells. The median proportion of CTCL cells was similar pre- and post-Ro (11% vs 12%; P=0.87).  DEG analysis identified 535 genes significantly modulated between pre- and post-Ro samples (349 genes pre-Ro, 186 genes post-R). Pathway enrichment analysis showed significant enrichment of interferon type II response signaling in pre-Ro samples.  Accordingly, DEG analysis demonstrated higher expression of interferon-related genes (IFITM1, IFI6, and IRF8) together with increased expression of IL32, a cytokine implicated in CTCL progression. Post-R CTCL cells upregulated several apoptosis-related genes (TNF, TNFSF10, FADD, and TNFRSF25) consistent with transcriptional priming toward apoptosis.

Conclusions:
We performed a phase 1 trial to test the priming ability of Ro to BV in CTCL. Ro-BV was well tolerated and produced high response rates, even in patients with absent/low baseline CD30. Spatial transcriptomics showed that romidepsin priming was associated with attenuation of interferon- and IL32-associated transcriptional programs and increased expression of apoptosis-associated genes. These findings suggest a biological rationale for epigenetic priming before BV and support further evaluation of Ro-BV as a bridging strategy for high-risk CTCL.

Luca Paruzzo, MD: University of Pennsylvania - Patents & Royalties